鉄剤静注の市場規模、シェア、成長分析、製品タイプ別、適応症別、流通チャネル別、地域別 - 産業予測、2025～2032年

鉄剤静注の市場規模は、2023年に32億米ドルと評価され、2024年の34億7,000万米ドルから2032年には66億1,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは8.4％で成長する見通しです。

世界の鉄剤静注市場は、人口のかなりの部分が罹患している鉄欠乏性貧血の罹患率の上昇を主因として、著しい成長を遂げています。鉄欠乏性貧血は酸素運搬能力の低下につながり、疲労や認知機能障害などの症状を引き起こします。高齢者は食事制限や慢性疾患などの要因により鉄欠乏症になりやすいため、人口動態の高齢化がさらに市場の需要を押し上げています。静脈内鉄分療法は、経口サプリメントに代わる効率的な選択肢を提供し、迅速な救済と患者の転帰改善を保証します。市場開拓企業は、革新的な製剤を開発し、安全性を高めるために研究開発に多額の投資を行っており、製品ラインと市場リーチを拡大するために戦略的に協力しています。認知度と需要が高まるにつれ、市場は継続的に拡大する構えです。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

鉄剤静注市場規模：製品タイプ別

• 市場概要
• 鉄デキストラン
• 鉄スクロース
• カルボキシマルトース鉄
• その他の製品タイプ

鉄剤静注市場規模：適応症別

• 市場概要
• 慢性腎臓病
• 炎症性腸疾患
• がん
• その他の病気

鉄剤静注市場規模：流通チャネル別

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

鉄剤静注市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Sanofi（France）
• Pharmacosmos A/S（Denmark）
• AbbVie Inc.（United States）
• Daiichi Sankyo Company, Ltd.（Japan）
• Pfizer Inc.（United States）
• Zydus Lifesciences Limited（India）
• Fresenius SE & Co. KGaA（Germany）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Akebia Therapeutics, Inc.（United States）
• Rockwell Medical, Inc.（United States）
• American Regent, Inc.（United States）
• AdvaCare Pharma（United States）
• Bayer AG（Germany）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Novartis AG（Switzerland）
• Shield Therapeutics plc（United Kingdom）
• Galenica Ltd.（Switzerland）
• CSL Limited（Australia）
• AMAG Pharmaceuticals, Inc.（United States）
• Covis Pharma GmbH（Switzerland）

結論と推奨事項

Intravenous Iron Drugs Market size was valued at USD 3.2 Billion in 2023 and is poised to grow from USD 3.47 Billion in 2024 to USD 6.61 Billion by 2032, growing at a CAGR of 8.4% during the forecast period (2025-2032).

The global intravenous iron drugs market is witnessing significant growth, primarily driven by the rising incidence of iron deficiency anemia, which affects a considerable portion of the population. This condition leads to decreased oxygen-carrying capacity, resulting in symptoms like fatigue and cognitive impairment. The aging demographic further fuels market demand, as older adults are more prone to iron deficiency due to factors such as dietary limitations and chronic illnesses. Intravenous iron therapy provides an efficient alternative to oral supplements, ensuring quicker relief and better patient outcomes. Market players are investing heavily in research and development to create innovative formulations and enhance safety, collaborating strategically to broaden their product lines and market reach. As awareness and demand increase, the market is poised for continued expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Intravenous Iron Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Intravenous Iron Drugs Market Segmental Analysis

Global Intravenous Iron Drugs Market is segmented by product type, indication, distribution channel and region. Based on product type, the market is segmented into Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, and Other Product Types. Based on indication, the market is segmented into Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Diseases. Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Intravenous Iron Drugs Market

The intravenous iron drugs market is significantly driven by the rising incidence of iron deficiency anemia globally. This condition is particularly prevalent among specific groups, including pregnant women, women of childbearing age, and individuals suffering from chronic illnesses. As awareness regarding the serious implications of iron deficiency continues to grow, coupled with the proven efficacy of intravenous iron therapies in effectively addressing this issue, there has been an upsurge in demand for these treatments. This heightened recognition and the ongoing need for effective solutions to combat iron deficiency anemia are key factors propelling the expansion of the intravenous iron drugs market.

Restraints in the Intravenous Iron Drugs Market

One significant restraint affecting the intravenous iron drugs market is the potential for adverse reactions or side effects during administration. Although these drugs are largely regarded as safe, the possibility of hypersensitivity reactions and infusion-related complications exists, including allergic responses, hypotension, and anaphylaxis. The fear of these adverse events may dissuade both healthcare professionals and patients from opting for intravenous iron therapy, thus restricting market growth. To address this challenge, it is crucial for manufacturers and healthcare providers to implement stringent patient selection criteria, effective monitoring, and careful administration protocols, all aimed at reducing the risk of complications and ensuring patient safety.

Market Trends of the Intravenous Iron Drugs Market

The intravenous iron drugs market is witnessing a significant trend towards innovation, characterized by the development of enhanced iron formulations designed to improve safety, efficacy, and patient convenience. Pharmaceutical companies are heavily investing in research to create advanced intravenous therapies that mitigate the drawbacks of traditional iron supplements, focusing on features such as extended dosing intervals, better tolerability, and minimized hypersensitivity risks. This shift not only enhances patient compliance but also marks a commitment to improving overall treatment outcomes. The ongoing push for novel formulations underscores a growing emphasis on patient-centric care within the intravenous iron drugs market, driving its growth and evolution.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Intravenous Iron Drugs Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Iron Dextran
• Iron Sucrose
• Ferric Carboxymaltose
• Other Product Types

Global Intravenous Iron Drugs Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Chronic Kidney Disease
• Inflammatory Bowel Disease
• Cancer
• Other Diseases

Global Intravenous Iron Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Intravenous Iron Drugs Market Size & CAGR (2025-2032)

• North America (Product Type, Indication, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmacosmos A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akebia Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rockwell Medical, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• American Regent, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AdvaCare Pharma (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shield Therapeutics plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galenica Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AMAG Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Covis Pharma GmbH (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations